Geographically North America dominated solid tumor market driven by best in class infrastructure, best in industry practices and higher spending by the citizens towards healthcare expenditure. North America was followed by Europe and Asia-Pacific as second and third largest market for solid tumor market. Asia Pacific is projected to have fastest growth, owing to rapidly developing medical infrastructure, increasing medical tourism, increased spending, and increasing awareness amongst population in developing nations such as China, and India in this region.
This report identifies the global solid tumor market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global solid tumor market.
This report segments global solid tumor market on the basis of drug and regional market as follows:
Solid Tumor Market research report is classified on the basis of drug. Some of the major drugs covered in this report are as follows: Avastin (bevacizumab), Afinitor (everolimus), Jevtana (cabazitaxel), Sutent (sunitinib), Tarceva (erlotinib), Taxotere (docetaxel), Zytiga (abiraterone acetate), Carboplatin, Cisplatin, Doxorubicin, Gemcitabine and Paclitaxel
Solid Tumor Market research report is classified on the basis of Type. Some of the major Types covered in this report are as follows: benign (non-cancerous) and malignant (cancerous)
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the solid tumor market. Some of the major companies’ profiles in detail are as follows:
Abbott Laboratories, Inc.
Biogen Idec, Inc.
Boehringer Ingelheim GmbH.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Solid Tumor Market– Market Forces
4.1.1. Increasing incidences solid tumors
4.1.2. Rising prevalence of different forms of metastatic cancers
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Solid Tumor Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Solid Tumor Market, By Type
6.1. Benign (non-cancerous)
6.2. Malignant (cancerous)
7. Solid Tumor Market, By Drug
7.1. Avastin (bevacizumab)
7.2. Afinitor (everolimus)
7.3. Jevtana (cabazitaxel)
7.4. Sutent (sunitinib)
7.5. Tarceva (erlotinib)
7.6. Taxotere (docetaxel)
7.7. Zytiga (abiraterone acetate)
8. Solid Tumor Market, By Geography
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.4. Rest of the World (RoW)
8.4.2. Rest of RoW
9. Solid Tumor Market – Market Entropy
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. AstraZeneca plc
10.2. Abbott Laboratories, Inc.
10.3. Amgen, Inc.
10.4. Biogen Idec, Inc.
10.5. Boehringer Ingelheim GmbH
10.6. Baxter International, Inc.
10.7. Bristol-Myers Squibb Company
10.8. F. Hoffmann-La Roche Ltd.
10.9. Eli Lilly and Company
10.10. Johnson & Johnson
10.11. GlaxoSmithKline plc
10.12. Kyowa Hakko Kirin Co., Ltd.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11.3. Research Methodology
11.5. Compilation of Expert Insights